

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The board of directors of Shanghai Henlius Biotech, Inc. (the “**Company**”) hereby announces that, based on the nomination by Mr. Jun Zhu (“**Mr. Zhu**”), the Chief Executive Officer of the Company (the “**CEO**”), Mr. Yingbo Mao (毛應波) (“**Mr. Mao**”) was appointed as the vice president and Chief Financial Officer (the “**CFO**”) of the Company with effect from 1 July 2024, and will report to Mr. Zhu, the CEO. Mr. Zhu ceased to serve as the CFO with effect from the same date but will remain serving as an executive director, the CEO and other positions of the Company.

Mr. Mao, aged 46, has over 20 years of financial management experience. Prior to joining the Company, Mr. Mao successively served as the CFO of Healthcare Holdings, the Co-Chief Financial Officer of the Healthcare Industry Committee and other positions of the Fosun Group (Fosun International Limited (stock code: 00656) and its subsidiaries) from March 2019 to June 2024. Prior to joining the Fosun Group, Mr. Mao was employed by Deloitte Touche Tohmatsu Certified Public Accountants, Coca-Cola (China) Investment Co., Ltd. (可口可樂(中國)投資有限公司), Bayer Healthcare Company Limited (拜耳醫藥保健有限公司), UCB and other companies. Mr. Mao obtained a bachelor's degree in economics from Shanghai University of Finance and Economics in July 2000, and accomplished the collaborative MBA project of BI Norwegian Business School and Fudan University and obtained a master's degree in business administration in July 2015. Mr. Mao is qualified as a Chinese Certified Public Accountant and holds the national legal professional qualification.

The board would like to take this opportunity to welcome Mr. Mao to join the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 1 July 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.